Self-Reported Long COVID and Its Association with the Presence of SARS-CoV-2 Antibodies in a Danish Cohort up to 12 Months after Infection.
N protein
PASC
SARS-CoV-2
SARS-CoV-2 antibodies
antibodies
long COVID
nucleocapsid antigen
post-COVID syndrome
post-acute-phase COVID-19
prolonged COVID
Journal
Microbiology spectrum
ISSN: 2165-0497
Titre abrégé: Microbiol Spectr
Pays: United States
ID NLM: 101634614
Informations de publication
Date de publication:
21 12 2022
21 12 2022
Historique:
pubmed:
10
11
2022
medline:
28
12
2022
entrez:
9
11
2022
Statut:
ppublish
Résumé
The majority of long coronavirus disease (COVID) symptoms are not specific to COVID-19 and could be explained by other conditions. The present study aimed to explore whether Danish individuals with a perception that they suffer from long COVID have antibodies against the nucleocapsid antigen, as a proxy for detecting previous infection. The study was conducted in February and March 2021, right after the second surge of the COVID-19 pandemic in Denmark. All members of the social media group on Facebook "Covidramte med senfølger" ("long COVID sufferers'') above the age of 17 years and living in Denmark were invited to participate in a short electronic questionnaire about long COVID risk factors and symptoms. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleocapsid (N) protein was detected in blood samples as a proxy for natural SARS-CoV-2 infection. The final study population comprised 341 participants (90.6% females) who completed blood sampling and answered the questionnaire. A total of 232 (68%) were seropositive (median age, 49.5 years; interquartile range [IQR], 41 to 55 years; 90.1% females). There was no significant difference between sexes and serostatus. Seronegative and seropositive individuals had a similar burden of symptoms that could be attributed to long COVID. Time since perceived COVID-19 was significantly longer in the group of seronegative individuals than the seropositive ones (
Identifiants
pubmed: 36350150
doi: 10.1128/spectrum.02537-22
pmc: PMC9769646
doi:
Substances chimiques
Antibodies, Viral
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0253722Références
Front Immunol. 2021 Jun 16;12:708523
pubmed: 34220870
J Clin Med. 2021 Sep 28;10(19):
pubmed: 34640486
Front Psychol. 2021 May 21;12:663799
pubmed: 34093358
Sci Rep. 2021 Dec 1;11(1):23216
pubmed: 34853374
Sci Rep. 2021 Jun 23;11(1):13153
pubmed: 34162913
Sci Rep. 2021 Feb 10;11(1):3455
pubmed: 33568776
Int J Environ Res Public Health. 2021 Aug 10;18(16):
pubmed: 34444180
JAMA Intern Med. 2022 Jan 1;182(1):19-25
pubmed: 34747982
Front Psychiatry. 2021 May 21;12:677934
pubmed: 34093286
Pathogens. 2022 Feb 19;11(2):
pubmed: 35215212
Emerg Microbes Infect. 2022 Dec;11(1):2762-2780
pubmed: 36302216
Commun Med (Lond). 2021;1(1):44
pubmed: 34870285
BMC Public Health. 2021 May 31;21(1):1023
pubmed: 34059034
Nat Med. 2021 Apr;27(4):626-631
pubmed: 33692530
Brain Behav Immun Health. 2021 Nov;17:100347
pubmed: 34549199
Lancet Infect Dis. 2020 Oct;20(10):1115-1117
pubmed: 32888409
Science. 2021 Feb 5;371(6529):
pubmed: 33408181
Lancet Reg Health Eur. 2021 Jul;6:100122
pubmed: 34027514